Recent years have witnessed substantial progress in the development of novel therapies for immunologic disorders such as rheumatoid arthritis (RA). Much of this progress has come from clinical research trials. While there is tremendous excitement surrounding new therapeutic approaches to RA a number of key questions relevant to their optimal use remain unanswered. For example, because many of these approaches are new, and have been assessed mainly in clinical trials, the potential for both long-term benefit and safety have not yet been defined. Because the approach to the treatment of RA is rapidly evolving, patients with RA may be confronted with a large and potentially confusing array of therapeutic options. At present, little is known about the processes by which RA patients make decisions concerning their therapy. Even in clinical trials that require informed consent, areas of concern and expectation that might affect patients' decision processes have not been explored. Moreover, it has been suggested that patients enrolling in clinical trials might inadequately represent the overall population of RA patients. For example, patients in trials may be better educated and from higher socioeconomic situations than RA patients in general. This has key implications for generalizing the results of trials to the broader population of RA patients. As the treatment of RA has rapidly progressed, access to or willingness to participate in clinical trials has become a more important consideration. In RA, it has been demonstrated that factors such as education and race can substantially impact outcome. Outside of rheumatology, it has been shown that ethnic background may affect patients decisions to pursue suboptimal therapeutic interventions as understanding related to the treatment of their rheumatic diseases. This project will utilize the technique of decision analysis to explore the factors that affect patients' choice of therapies. By including a diverse group of patients and assessing characterisitcs related to both the patient as well as the disease process, we hope to gain an understanding that should facilitate access of RA patients diverse in race, sex, gender and social status to optimal therapies for their disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
5P60AR040770-09
Application #
6310393
Study Section
Special Emphasis Panel (ZAR1-MHG-B (J1))
Project Start
1991-08-01
Project End
2001-02-28
Budget Start
Budget End
Support Year
9
Fiscal Year
2000
Total Cost
$112,459
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Malcarne, Vanessa L; Hansdottir, Ingunn; McKinney, Ann et al. (2007) Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol 34:359-67
Leake, John A D; Albani, Salvatore; Kao, Annie S et al. (2004) Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 23:756-64
Meyer, Markus; Belke, Darrell D; Trost, Susanne U et al. (2004) A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. FASEB J 18:1312-4
Johnson, Kristen; Goding, James; Van Etten, Deborah et al. (2003) Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 18:994-1004
Groessl, Erik J; Kaplan, Robert M; Cronan, Terry A (2003) Quality of well-being in older people with osteoarthritis. Arthritis Rheum 49:23-8
Kaplan, Robert M (2003) The significance of quality of life in health care. Qual Life Res 12 Suppl 1:3-16
La Cava, Antonio; Massa, Margherita; Mendivil, Alberto et al. (2002) Genetic immunization maps T cell (auto)immune responses to self antigens homologous to exogenous proteins. Autoimmunity 35:105-10
Prakken, Berent J; Roord, Sarah; van Kooten, Peter J S et al. (2002) Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheum 46:1937-46
Kaplan, Robert M (2002) Quality of life: an outcomes perspective. Arch Phys Med Rehabil 83:S44-50
Silverman, Gregg J; Goodyear, Carl S (2002) A model B-cell superantigen and the immunobiology of B lymphocytes. Clin Immunol 102:117-34

Showing the most recent 10 out of 94 publications